Subscribe Become an Author Sign Up Log In

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

A Market Review Of DNA-encoded Libraries Technology In Drug Discovery

   1628
A Market Review Of DNA-encoded Libraries Technology In Drug Discovery

The interest of pharma organizations to DNA-encoded chemical libraries (DEL) technology has been growing over the years, with numerous pharma organizations now having their own screening programs using DELs, or outsourcing capabilities from specialized DEL providers.

This report provides a bird's view on the DEL market, including a brief summary of DEL technology benefits and limitations, key players, major research deals, and several examples of successful hit discovery programs using DELs. 

A Race For Better Gene Editing Tech Is On

   327
A Race For Better Gene Editing Tech Is On

A transformative technology for gene editing - clustered regularly interspaced short palindromic repeats (CRISPR) -- has become ubiquitous, at least in research laboratories, where scientists efficiently adopted CRISPR technology to manipulate genes of interest. Still, applying it for humans is associated with greater risks and faces ethical issues. However, alongside a too reckless experiment of a Chinese scientist who edited babies’ genomes, plenty of companies have made well-thought progress toward transferring gene editing technologies into the clinic. Here we make a brief but pithy review on up-to-date gene editing approaches and start-up companies active in this area.

Top Companies At The Forefront Of RNA Therapeutics Development

   296
Top Companies At The Forefront Of RNA Therapeutics Development

Alongside the topic of gene editing technologies that keeps making headlines these days, there is also a wave of breakthroughs in the field of RNA-targeting medicines, primarily falling into the following two categories: antisense oligonucleotides (ASO), and RNA interference (RNAi) technologies. (another promising approach, dealing with editing RNA itself by ADAR enzymes, is not covered in this post). 

Microbiome: Can Human Microbes Become A Panacea?

   188
Microbiome: Can Human Microbes Become A Panacea?

The microbiome is implicated in a number of metabolic pathways and communicates closely with our body in health and diseases. Imbalance of microflora is linked to obesity, diabetes, allergies, cancer, and even depression and autism. However, these facts have been ignored for decades. But today, the microbiome market is catching up, attracting considerable investments. The Wall Street Journal reported in 2018 that “from 2011 through 2015, venture funding in microbiome firms soared 458.5 percent to $114.5 million, while overall venture investment grew 103.4 percent to $75.29 billion.